PhD Enquiry - Transcription Dysfunction in Disease
School of Medicine, Dentistry and Biomedical Sciences
- Location
- Belfast, United Kingdom
- Funding
- See university guidance
- Application deadline
- See university guidance
About the project
The Functional Genomics Group focusses on the use of cutting-edge genomics technologies to investigate transcription factor function and de-regulation in cancer with a particular interest in the p53 family.
We believe that a better understanding of the genome-wide targets, mechanism of action and consequences of de-regulation of key transcription factors; will allow us to identify cancer specific dependencies, that represent “Achilles heels”, exploitable with novel treatment strategies to improve patient outcomes.
- Dr Simon McDade: School of Medicine, Dentistry and Biomedical Sciences
Contact info
- View Academic Profile
- askmhls@qub.ac.uk
- +44 (0)28 9097 2183
Research Interests
Open to PhD applications in the field of
Make a PhD enquiry
- Transcription dysfunction in disease
- Functional genomics and integrative bioinformatics
- Identification of novel genomically informed treatment strategies
Current Research Opportunities
- Using epigenetic modifiers in combination with 5-FU based chemotherapy to elicit tumour specific immune responses and immunogenic cell death in colorectal cancer.
- Novel approaches to uncovering effects of anti-cancer agents targeting epigenetic modifiers.
- Integrative Functional Genomics of Chemotherapy Response and Resistance in Colorectal Cancer
- Integrative Genomic Mapping of Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
- Integrative Genomic Analysis of Androgen Deprivation Therapy Resistance in Prostate Cancer
- Using epigenetic modifiers in combination with 5-FU based chemotherapy to elicit tumour specific immune responses and immunogenic cell death in colorectal cancer.
- Novel approaches to uncovering effects of anti-cancer agents targeting epigenetic modifiers.
Public outreach & key achievements
- Academic Lead FMHLS Genomics Core Technology Unit
- Co-Investigator on CRUK Colorectal Cancer Program Grant funded by Bobby Moore Foundation
- Co-Investigator PCUK-Movember QUB-Manchester Centre of Excellence
- Pre-Clinical Lead CRUK New Agents Committee sponsored first-in-human trial of CDC7 inhibitor to exploit p53 deficiency
Discover More
- Faculty of Medicine, Health and Life Sciences
- School of Medicine, Dentistry and Biomedical Sciences
- The Patrick G Johnston Centre for Cancer Research
- Genomics
- Gastro-Intestinal Focus Group